โ Scribed by Brian A. Brigham
No coin nor oath required. For personal study only.
Small cell anaplastic lung cancer is increasingly considered to be potentially curable. The opinion that this tumor is a rapidly proliferating one has not been substantiated by kinetic studies, and for this reason late relapse may occur in complete remitters. Differential rates of response/relapse in different tumor sites may be explained on the basis of heterogeneity in tumor kinetics.
๐ SIMILAR VOLUMES
The development of drug resistance limits the survival or patients with small cell anaplastic carcinoma of the lung (SCLC). The present study was undertaken to overcome this problem by administering two alternating noncross resistant combination chemotherapy regimens. One-hundred-one patients were e
Twelve patients with small-cell anaplastic carcinoma of the lung were treated with vincristine 1 mg/m2 i.v. day 1, adriamycin 50 mg/M2 i.v. day 1, cyclophosphamide 1,000 mg/m2 i.v. day 1, and etoposide 80 mg/m2 i.v. day 2, 4, 6 given on an outpatient basis and repeated at 3-week intervals. As consol